drugset / Trial / NCT03370172
A Study of BAX 888 in Male Adults With Severe Hemophilia A
Phase 1/2
Completed
4 enrolled
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire · collabTakeda Development Center Americas, Inc. · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A in male adults. Participants will receive one infusion with BAX 888 at the hemophilia treatment center. During the study, participants will visit their study clinic multiple times.
Timeline
- Start
- 2018-02-27
- Primary completion
- 2024-07-09
- Completion
- 2024-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAX 888 | Gene therapy (AAV / viral vector) | 2e+12 unknown | Intravenous |
| Subject | BAX 888 | Gene therapy (AAV / viral vector) | 6e+12 unknown | Intravenous |